The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 February 2026•

1 min read

Madrigal Expands MASH Pipeline with Strategic Licensing Deal, Bolstering Rezdiffra Potential

Logos of Mineralys Therapeutics and Jefferies on an orange background with financial charts, chemical structures, microscopes, lab equipment, vials, and pills.

Madrigal Pharmaceuticals (MDGL) has significantly expanded its metabolic dysfunction-associated steatohepatitis (MASH) pipeline by securing exclusive global licensing rights to six preclinical siRNA programs. This strategic agreement was made with Suzhou Ribo Life Science Co. Ltd. The deal involves an upfront payment of $60 million, alongside potential milestone payments that could reach up to $4.4 billion upon achieving specified development and commercial objectives. This move aims to develop innovative combination therapies, leveraging Madrigal's recently approved drug Rezdiffra, to enhance MASH treatment outcomes. The expansion reinforces Madrigal's commitment to strengthening its MASH franchise and addressing the serious liver disease with advanced therapeutic solutions. This proactive step positions Madrigal for potential long-term growth and market leadership in MASH treatment.